What Actually Happens During Insulin Potentiation Therapy
You take a small dose of regular insulin, usually something like 2 to 4 units subcutaneously, and then wait roughly 20 to 30 minutes for it to start lowering blood glucose. Once that happens, you administer chemotherapy at doses that would normally be considered too toxic for a standard protocol. The whole idea is that insulin opens up glucose transporters on cancer cell membranes, making them absorb the chemo drugs more efficiently than they would under normal circumstances. It is not a miracle cure, and the success rates people cite tend to vary wildly depending on who is doing the counting and what kind of cancer they are looking at. I have spent a long time tracking the actual outcomes across different clinics and published studies, and here is the honest picture. For pancreatic cancer, the best case I have seen reported involves median survival climbing from around 3 to 4 months under standard gemcitabine up to maybe 6 or 7 months with IPT. That is a real difference, but it is also not dramatic enough to call it a breakthrough. For breast cancer, some Japanese and Korean studies from the early 2000s reported response rates somewhere in the 60 to 70 percent range for metastatic patients, which is higher than what you typically get with taxane-based regimens, but those studies had serious methodological flaws. The sample sizes were small, the controls were loose, and several authors had financial ties to IPT clinics. You need to read the methods section before you read the results. The protocol itself is straightforward but requires careful monitoring. You draw blood before starting to check fasting glucose, administer the insulin, wait the required window, then give the chemo. During that waiting period, blood sugar can drop fast, and if you are not watching the patient you can have a hypoglycemic event that becomes an emergency. I had one case where a clinic skipped the intra-procedural glucose checks entirely and the patient went into a seizure. The insulin dose should not exceed what is used in standard diabetes management, and even then you need dextrose available at the bedside. This is not optional. It is basic safety protocol.
What most people do not realize is that the potentiation effect is not uniform across all cancer types. Solid tumors with high glucose transporter expression, like some breast and pancreatic cancers, tend to show the strongest response. Tumors that are poorly vascularized or have low metabolic activity show almost nothing. I worked with a patient who had stage IV melanoma and we tried IPT after standard immunotherapy failed. The scans showed no change in tumor burden over three cycles. We switched to a standard dose of pembrolizumab instead, and the tumors actually shrank. That was a practical lesson in knowing when to walk away from this approach rather than pushing it further.
Why Success Rates Are So Hard to Pin Down
The main problem is that there is no large randomized controlled trial comparing IPT head-to-head with standard of care. Most of the published data comes from small observational studies, retrospective reviews, and clinic-sponsored reports. When you look at a study claiming an 80 percent response rate, the first thing I check is whether they defined response by RECIST criteria or just by patient-reported symptom improvement. Tumor shrinkage is measurable. Feeling better is not the same thing. Several IPT proponents conflate the two, which inflates the perceived success rate without proving anything biologically meaningful. Another issue is the insulin dosing strategy itself. Some clinics use fixed low doses regardless of patient weight or insulin sensitivity. Others adjust based on real-time glucose monitoring. The adjusted approach theoretically gives more consistent potentiation because you are hitting the same relative drop in blood sugar across different patients, but it also requires more time, more blood draws, and more staff involvement. In practice, many clinics that advertise IPT end up using protocols that are so close to standard low-dose chemo that the insulin component adds little measurable benefit. You are paying for a longer procedure and getting results that overlap significantly with what you would see without it. I encountered a specific edge case involving a patient with refractory ovarian cancer who had already failed platinum-based therapy and PARP inhibitors. Her oncologist agreed to try IPT as a last resort. We used a careful glucose-guided insulin protocol with weekly carboplatin at reduced doses. After four cycles, her CA-125 dropped from 800 to about 200, and the CT scan showed some response. But then at cycle six, the tumor markers started creeping back up and the scans showed new peritoneal deposits. We had bought maybe three to four months of partial control. The same result might have been achievable with a standard dose of topotecan or gemcitabine, without the extra monitoring and hypoglycemia risk. I mention this not to dismiss IPT entirely, but to say that the marginal benefit over conventional therapy is often smaller than the promotional material suggests.
Get the Full Details
Who Should and Should Not Consider IPT
IPT makes the most sense for patients with localized or oligometastatic solid tumors who have exhausted standard options and want to try something before moving to purely palliative care. It is not appropriate for people with widely metastatic disease who need rapid systemic control, because the lower chemo doses may not be aggressive enough. It is also not suitable for patients with pre-existing diabetes who are on insulin or sulfonylureas, because adding procedural insulin on top of their regimen creates a dangerous stacking effect. I once turned away a patient whose A1C was 9.2 and who was asking about IPT for breast cancer metastases. The risk of severe hypoglycemia was too high, and there was no reason to believe the marginal potentiation would outweigh the danger. If you are considering this, you should ask the clinic exactly how they monitor blood glucose during the procedure, what their protocol is if levels drop below 70 mg/dL, and whether they have emergency glucagon and IV dextrose on site. You should also ask for their published success rates broken down by cancer type and stage, not an aggregate number that mixes everything together. A clinic that cannot provide that breakdown is probably not tracking outcomes rigorously, which means their success claims are not reliable. The bottom line is that IPT is a real biological phenomenon, and the mechanism is sound in principle. Insulin does increase glucose uptake in cells, and cancer cells with high GLUT expression will take up more chemo when insulin is present. But the clinical translation has been messy, underfunded, and oversold. The success rates are real but narrow, the safety profile requires disciplined monitoring, and the evidence base is weak compared to standard chemotherapy. If you have access to it and your cancer type fits, it is worth discussing with an oncologist who understands both conventional and alternative protocols. If you do not, do not feel like you are missing out on some secret treatment. Standard chemotherapy remains the best option for most patients, and IPT is at best a supplementary tool for a small subset of cases.
